English

Last day of trading in BTA in Initiator Pharma A/S

Report this content

PRESS RELEASE                

13 August 2021

In July 2021, Initiator Pharma A/S (”Initiator Pharma”) conducted a rights issue in which the general public was given the opportunity to subscribe. Through the rights issue, a total of 7,958,628 shares were issued. The rights issue has now been registered at the Danish Business Authority and the last day of trading in BTA (paid for shares) is on the 18th of August 2021. The stop date will be on the 20th of August 2021.

A total of 7,958,628 new shares have been registered at the Danish Business Authority. These are estimated to be distributed to each VP account/depot on the 24th of August 2021 for shareholders who have subscribed for shares with preferential rights and as soon as possible for subscribers without preferential rights. After registration, the number of shares in Initiator Pharma amount to 43,772,462 and the share capital amounts to DKK 4,596,108.51.

For further information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO

Telephone number: +45 6126 0035

E-mail: ceo@initiatorpharma.com

The information was submitted for publication, through the agency of the contact person set out above on 13 August 2021 at 17:00.

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. Initiator Pharma is listed on Spotlight Stockmarket (ticker: INIT).

About Erectile dysfunction (ED)

Erectile dysfunction is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. ED affects more than 150 million men worldwide and that number is expected to increase to more than 320 million by 2025, fuelled by aging demographics and increasing prevalence of lifestyle diseases such as diabetes, and performance anxiety. The number of ED patients is most likely grossly underestimated, particularly for Psychogenic patient segment. ED patients have decreased quality of life due to various psychosocial factors such as low self-esteem, depression, sadness, anger, frustration, anxiety, medication, and relationship problems (1,2,3). Erectile dysfunction can be divided into two main categories – Organic and Psychogenic ED – that requires different treatments. Initiator Pharma is developing IPED2015 and IP2018, respectively, for these similar but separate patient segments.

  1. Shabsigh R, et al. (1998) Increased incidence of depressive symptoms in men with erectile dysfunction. Urology52(5):848–852.
  2. Mccabe MP, Althof SE (2014) A systematic review of the psychosocial outcomes associated with erectile dysfunction: Does the impact of erectile dysfunction extend beyond a man’s inability to have sex? J Sex Med11(2):347–363.
  3. Nguyen HMT, Gabrielson AT, Hellstrom WJG (2017) Erectile Dysfunction in Young Men—A Review of the Prevalence and Risk Factors. Sex Med Rev5(4):508–520.

Documents & Links